- Home
- NRIX vs SVM Comparison
NRIX vs SVM Comparison
Compare NRIX & SVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- SVM
- Stock Information
- Founded
- NRIX 2009
- SVM N/A
- Country
- NRIX United States
- SVM Canada
- Employees
- NRIX N/A
- SVM N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- SVM Precious Metals
- Sector
- NRIX Health Care
- SVM Basic Materials
- Exchange
- NRIX Nasdaq
- SVM Nasdaq
- Market Cap
- NRIX 970.1M
- SVM 1.1B
- IPO Year
- NRIX 2020
- SVM N/A
- Fundamental
- Price
- NRIX $11.64
- SVM $4.78
- Analyst Decision
- NRIX Strong Buy
- SVM Strong Buy
- Analyst Count
- NRIX 16
- SVM 1
- Target Price
- NRIX $29.56
- SVM $6.75
- AVG Volume (30 Days)
- NRIX 978.7K
- SVM 6.2M
- Earning Date
- NRIX 07-09-2025
- SVM 08-07-2025
- Dividend Yield
- NRIX N/A
- SVM 0.52%
- EPS Growth
- NRIX N/A
- SVM 40.00
- EPS
- NRIX N/A
- SVM 0.28
- Revenue
- NRIX $88,381,000.00
- SVM $298,895,000.00
- Revenue This Year
- NRIX $34.87
- SVM $1.10
- Revenue Next Year
- NRIX N/A
- SVM $26.47
- P/E Ratio
- NRIX N/A
- SVM $18.07
- Revenue Growth
- NRIX 41.86
- SVM 38.90
- 52 Week Low
- NRIX $8.18
- SVM $2.87
- 52 Week High
- NRIX $29.56
- SVM $5.32
- Technical
- Relative Strength Index (RSI)
- NRIX 46.20
- SVM 56.16
- Support Level
- NRIX $11.13
- SVM $4.43
- Resistance Level
- NRIX $11.92
- SVM $4.88
- Average True Range (ATR)
- NRIX 0.77
- SVM 0.24
- MACD
- NRIX -0.15
- SVM -0.02
- Stochastic Oscillator
- NRIX 11.79
- SVM 43.95
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About SVM Silvercorp Metals Inc.
Silvercorp Metals Inc is a mineral exploration company, engaged in the acquisition, exploration, development, and mining of mineral properties. The company's producing mines are located in China, and exploration and development projects are located in China and Ecuador. Its project portfolio comprises the El Domo copper-gold and the Condor gold project in Ecuador. In addition, it operates several silver-lead-zinc mines at the Ying Mining District in Henan Province, China, and the GC silver-lead-zinc mine in Guangdong Province, China. A majority of the company's revenue is generated through the sale of silver concentrates. Its reportable operating segments are the Ying Mining District and GC Mine in China, which derive maximum revenue, and the El Domo and Condor projects in Ecuador.